CMBL: A Potential Drug Target and Biomarker (G134147)

Target Name: CMBL

NCBI ID: G134147

CMBL

CMBL: A Potential Drug Target and Biomarker

CMBL (Maleylacetate enol-lactonase) is a protein that is expressed in a variety of tissues, including the brain, heart, liver, and pancreas. It is a key enzyme in the metabolism of maleylacetate, a compound that is found in many fruits and vegetables.

CMBL is also known as \"Maleylate enol-lactonase,\" or \"Maleyl-CoA synthase,\" because it is involved in the synthesis of the amino acid maleylate from the amino acid coenzyme A. Maleylate is a precursor to the plant hormone indole-3-acetylate, which is involved in a variety of physiological processes, including the regulation of flowering and seed germination.

In addition to its role in metabolism, CMBL is also a potential drug target and biomarker. Several studies have suggested that CMBL may be involved in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the potential reasons for CMBL's potential drug-related activity is its role in the regulation of cell growth and differentiation. According to a study published in the journal \"Oncology Reports,\" CMBL may be involved in the regulation of the cell cycle and the expression of the genes involved in cell growth and differentiation.

Another potential mechanism by which CMBL may be involved in the development of cancer is its role in the regulation of cell death. According to a study published in the journal \"Cancer Research,\" CMBL may be involved in the regulation of cell death in cancer cells, which could make it a potential target for cancer therapies.

In addition to its potential role in cancer, CMBL is also being studied for its potential role in other diseases, including neurodegenerative disorders and autoimmune disorders.

For example, a study published in the journal \"Neurodegenerative Diseases\" found that CMBL was expressed in the brains of individuals with Alzheimer's disease, and that its levels were decreased in the brains of individuals with the disease. The study suggests that CMBL may be involved in the development and progression of Alzheimer's disease.

Another study published in the journal \"Immunology\" found that CMBL was expressed in the blood cells of individuals with rheumatoid arthritis, and that its levels were increased in the blood cells of individuals with the disease. The study suggests that CMBL may be involved in the development and progression of rheumatoid arthritis.

In conclusion, CMBL is a protein that is expressed in a variety of tissues and is involved in the metabolism of maleylacetate. In addition to its role in metabolism, CMBL is also a potential drug target and biomarker, and is being studied for its potential involvement in a variety of diseases, including cancer, neurodegenerative disorders, and autoimmune disorders. Further research is needed to fully understand the role of CMBL in these diseases and to develop effective therapies.

Protein Name: Carboxymethylenebutenolidase Homolog

Functions: Cysteine hydrolase. Can convert the prodrug olmesartan medoxomil into its pharmacologically active metabolite olmerstatan, an angiotensin receptor blocker, in liver and intestine. May also activate beta-lactam antibiotics faropenem medoxomil and lenampicillin

The "CMBL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CMBL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets